

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Ramnarayan et al.

Serial No.: 09/709,905

Filed: November 10, 2000

For: USE OF COMPUTATIONALLY DERIVED

PROTEIN STRUCTURES OF GENETIC

POLYMORPHISMS IN

PHARMACOGENOMICS FOR DRUG

DESIGN AND CLINICAL APPLICATIONS

Art Unit: 1631

Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number <u>EV 175670982 US</u>

Date of Deposit October 08, 2002

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as First Class Priority Mail in an

envelope addressed to:

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202, on this date.

10/08/02 Date

## TRANSMITTAL LETTER

Commissioner for Patents Arlington, VA 22202

Dear Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), and the cited reference for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application but before either a Final Office Action or Notice of Allowance in the above-referenced application, a fee for filing this statement is included herewith. However, should said fee be either missing or incorrect, the Commissioner is authorized to charge deposit account No. 50-1213, for the appropriate fee as stated below:

The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

By:

Stephanie Seidman, Reg. No. 33,779

Attorney Docket No. 24737-1906C

Address all correspondence to:
Stephanie Seidman, Esq.
Heller Ehrman White & McAuliffe LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246

Telephone: (858)450-8403 Facsimile: (858)587-5360 Email: sseidman@HEWM.com **RECEIVED** 

OCT 1 5 2002

**TECH CENTER 1600/2900** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

cant: erial No.: Ramnarayan et al.

Filed:

09/709,905 November 10, 2000

For:

USE OF COMPUTATIONALLY DERIVED

PROTEIN STRUCTURES OF GENETIC

POLYMORPHISMS IN

PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS

Art Unit:

1631

Examiner:

Unassigned

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 175670982 US

Date of Deposit October 08, 2002

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as First Class Priority Mail in an

envelope addressed to:

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202, on this date.

10/08/02

Date

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Commissioner for Patents Arlington, VA 22202

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and the cited reference are provided herewith in connection with the above-captioned application.

RECEIVED

U.S.S.N. 09/709,905
RAMNARAYAN et al.

Supplemental Information Disclosure Statem nt

The document listed on the Form PTO-1449 and supplied herewith is in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

By: Stephanie Seidman

Registration No. 33,779

Attorney Docket No. 24737-1906C

Address all correspondence to:
Stephanie Seidman, Esq.
Heller Ehrman White & McAuliffe LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246

Telephone: (858) 450-8400 Facsimile: (858) 587-5360 EMAIL: sseidman@HEWM.com